BCL2 and lymphoma: In DHL/THL model, OTX015 (Birabresib) combined with BCL2 antagonist (such as Venetoclax) synergically inhibited the malignant proliferation of DHL/THL cells [262], supporting the combining use of BETi and BCL2 inhibitors against MYC-driven lymphoma.